Finkelstein Thompson LLP Investigates Potentially Unfair Buyout of Humana Inc.
July 06 2015 - 3:53PM
Business Wire
Finkelstein Thompson LLP is investigating potential claims on
behalf of shareholders of Humana Inc. (“Humana” or the
“Company”) (NYSE:HUM), concerning the Company’s proposed
acquisition by Aetna Inc. Under the terms of the proposal, Humana
shareholders will receive $125.00 in cash and 0.8375 Aetna
common shares for each share of Humana common stock they own or
$230.11 per share. The entire transaction is valued at
approximately $37 billion.
The investigation is focused on whether Humana’s Board of
Directors breached its fiduciary duty in failing to maximize
consideration to shareholders, the potential unfairness of the
consideration to shareholders, the process by which the Board of
Directors considered the transaction, and potential conflicts of
interest among Humana’s Board of Directors’ members.
If you are interested in discussing your rights as a Humana
shareholder, or have information relating to this investigation,
please contact Finkelstein Thompson’s Washington, DC offices at
(877) 337-1050 or (202) 337-8000, or by email
at contact@finkelsteinthompson.com.
Finkelstein Thompson LLP has spent over three decades delivering
outstanding representation to institutional and individual clients
in financial litigation, and has been appointed as lead or
co-counsel in dozens of shareholder class actions. Indeed, the firm
has served in leadership roles in cases that have recovered over $1
billion for investors and consumers.
To learn more about Finkelstein Thompson LLP, please visit our
website at www.finkelsteinthompson.com. Attorney advertising.
Prior results do not guarantee similar outcomes.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150706005820/en/
Finkelstein Thompson LLPRosalee B. C. Thomas,
877-337-1050rbcthomas@finkelsteinthompson.com
Humana (NYSE:HUM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Humana (NYSE:HUM)
Historical Stock Chart
From Jul 2023 to Jul 2024